Emergent BioSolutions announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business. As a result of the strategic shift away from Emergent?s services business, the company is eliminating the chief operating officer (COO) role. As such, Adam Havey, executive vice president and current COO, will be leaving the company on September 30, 2023.

Bill Hartzel, senior vice president and head of bioservices, will assume responsibility for manufacturing operations and will join the executive management team reporting to the interim CEO.